Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
M&A
Biotech
Biopharma Q2 VC hit highest level since ’22, while M&A slowed
Venture capital in biopharma rose to $9.2 billion across 215 deals in the second quarter of this year—the highest funding level since 2022.
Gabrielle Masson
Aug 23, 2024 4:00am
Bayer pharma BD chief says group overhaul not slowing deals
Aug 15, 2024 2:30pm
Boehringer offers up to $1.3B for checkpoint inhibitor biotech
Jul 29, 2024 10:31am
AbbVie axes Alzheimer's program amid 'evolving landscape'
Jul 25, 2024 10:49am
AbbVie turns up the M&A heat with $250M Celsius buy
Jun 27, 2024 11:00am
Trial sites 'hottest' pharma services category for PE: PitchBook
Jun 20, 2024 12:01am